BeiGene, Ltd.
ANTI-OX40 ANTIBODIES AND METHODS OF USE

Last updated:

Abstract:

The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), a pharmaceutical composition comprising said antibody, and use of the antibody or the composition for treating a disease, such as cancer. In particular, the anti-OX40 antibody of the present invention does not interfere with the binding of OX40-ligand to its receptor.

Status:
Application
Type:

Utility

Filling date:

22 May 2019

Issue date:

15 Jul 2021